MAP2K7 and urinary bladder cancer: Pharmaceutical inhibition of TPL2 phosphorylation or reduction of intracellular cAMP level may help develop new therapeutic strategies to enhance the efficacy of IFN-α and MEK inhibitors in bladder cancer treatment.